At a glance
- Originator Sanofi-Synthelabo
- Class Antidepressants; Anxiolytics
- Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 1D receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 23 May 1995 Discontinued-Preclinical for Anxiety disorders in France (Unknown route)